Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $6.82 USD
Change Today -0.39 / -5.41%
Volume 37.7K
AQXP On Other Exchanges
Symbol
Exchange
NASDAQ GM
As of 8:10 PM 06/29/15 All times are local (Market data is delayed by at least 15 minutes).

aquinox pharmaceuticals inc (AQXP) Snapshot

Open
$6.99
Previous Close
$7.21
Day High
$7.44
Day Low
$6.80
52 Week High
03/11/15 - $12.28
52 Week Low
10/13/14 - $5.50
Market Cap
73.1M
Average Volume 10 Days
46.3K
EPS TTM
$-2.50
Shares Outstanding
10.7M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for AQUINOX PHARMACEUTICALS INC (AQXP)

Related News

No related news articles were found.

aquinox pharmaceuticals inc (AQXP) Related Businessweek News

No Related Businessweek News Found

aquinox pharmaceuticals inc (AQXP) Details

Aquinox Pharmaceuticals Inc., a clinical-stage pharmaceutical company, engages in discovering and developing targeted therapeutics for diseases in the areas of inflammation and immuno-oncology. The company primarily focuses on anti-inflammatory product candidates targeting SHIP1, a key regulator of a cellular signaling pathway in immune cells. Its lead product candidate is AQX-1125, a small molecule activator of SHIP1 that is in Phase II clinical trials for chronic obstructive pulmonary disease, bladder pain syndrome/interstitial cystitis, and atopic dermatitis. The company was formerly known as 6175813 Canada Inc. and changed its name to Aquinox Pharmaceuticals Inc. in March 2006. Aquinox Pharmaceuticals Inc. was founded in 2003 and is headquartered in Vancouver, Canada.

24 Employees
Last Reported Date: 05/12/15
Founded in 2003

aquinox pharmaceuticals inc (AQXP) Top Compensated Officers

Co-Founder, Chairman, Chief Executive Officer...
Total Annual Compensation: $365.0K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $181.1K
Chief Medical Officer and Senior Vice Preside...
Total Annual Compensation: $302.4K
Compensation as of Fiscal Year 2014.

aquinox pharmaceuticals inc (AQXP) Key Developments

Aquinox Pharmaceuticals Inc. Announces Results from its Phase 2 LEADERSHIP Randomized Clinical Trial

Aquinox Pharmaceuticals Inc. announced results from its Phase 2 LEADERSHIP randomized clinical trial investigating the therapeutic potential of AQX-1125 in treating pain in patients with bladder pain syndrome/interstitial cystitis (BPS/IC). While AQX-1125 demonstrated a reduction in pain for patients on AQX-1125 as compared to those patients on placebo following six weeks of treatment, the difference did not reach statistical significance (p = 0.061). The mean change in pain score for patients on 200mg oral, once daily AQX-1125 vs. placebo was a reduction of 2.4 vs. 1.3 points, respectively. The primary endpoint was based on an 11-point numeric rating scale recorded by electronic diary. Approximately 49% of patients receiving AQX-1125 demonstrated a 2-point or greater reduction in pain compared to 34% of patients receiving placebo. Secondary endpoints are currently being analyzed and will be reported at a future meeting. Consistent with past results, the LEADERSHIP trial demonstrated AQX-1125 to be well tolerated. No serious adverse events were recorded during the trial. The overall adverse event rate was similar between AQX-1125 and placebo. The most frequently reported adverse events were gastrointestinal disorders (32% for AQX-1125 vs. 34% for placebo).

Aquinox Pharmaceuticals Inc. - Special Call

To discuss the results from its phase 2 LEADERSHIP randomized clinical trial investigating the therapeutic potential of AQX-1125 in treating pain in patients with bladder pain syndrome/interstitial cystitis (BPS/IC)

Aquinox Pharmaceuticals Inc. Presents at Jefferies 2015 Global Healthcare Conference, Jun-03-2015 08:30 AM

Aquinox Pharmaceuticals Inc. Presents at Jefferies 2015 Global Healthcare Conference, Jun-03-2015 08:30 AM. Venue: The Grand Hyatt Hotel, New York, New York, United States. Speakers: David J. Main, Co-Founder, Chairman, Chief Executive Officer and President.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
AQXP:US $6.82 USD -0.39

AQXP Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for AQXP.
View Industry Companies
 

Industry Analysis

AQXP

Industry Average

Valuation AQXP Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 2.6x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact AQUINOX PHARMACEUTICALS INC, please visit www.aqxpharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.